Free Trial
NASDAQ:ORGS

Orgenesis (ORGS) Stock Price, News & Analysis

Orgenesis logo
$1.33 -0.20 (-13.07%)
As of 07/3/2025 12:46 PM Eastern

About Orgenesis Stock (NASDAQ:ORGS)

Key Stats

Today's Range
$1.28
$1.49
50-Day Range
$1.33
$2.48
52-Week Range
$0.87
$10.80
Volume
12,038 shs
Average Volume
8,399 shs
Market Capitalization
$6.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ORGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter.

ORGS Stock News Headlines

Orgenesis Delays Filing of Quarterly Report
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
Orgenesis secures $5M equity investment from Williamsburg Venture
Orgenesis Inc. Reports Q3 2024 Financial Results
Orgenesis Provides Third Quarter 2024 Business Update
See More Headlines

ORGS Stock Analysis - Frequently Asked Questions

Orgenesis' stock was trading at $1.89 at the beginning of 2025. Since then, ORGS shares have decreased by 29.6% and is now trading at $1.33.

Orgenesis Inc. (NASDAQ:ORGS) posted its quarterly earnings results on Friday, August, 11th. The company reported ($1.50) EPS for the quarter, missing analysts' consensus estimates of $0.60 by $2.10. The company had revenue of $6.98 million for the quarter.

Shares of Orgenesis reverse split before market open on Wednesday, September 25th 2024.The 1-10 reverse split was announced on Monday, September 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

The following companies are subsidiaries of Orgenesis: Koligo Therapeutics, and Tamir Biotechnology Inc.

Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Orgenesis investors own include NVIDIA (NVDA), Energy Transfer (ET), BioLineRx (BLRX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and Enbridge (ENB).

Company Calendar

Last Earnings
8/11/2023
Today
7/06/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ORGS
Fax
N/A
Employees
150
Year Founded
2008

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$55.36 million
Net Margins
-3,827.81%
Pretax Margin
-3,931.93%

Debt

Sales & Book Value

Annual Sales
$662 thousand
Price / Cash Flow
N/A
Book Value
($6.58) per share
Price / Book
-0.20

Miscellaneous

Free Float
4,527,000
Market Cap
$6.38 million
Optionable
No Data
Beta
0.47

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:ORGS) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners